Myositis-specific Antibodies: Overview and Clinical Utilization.

Area of Science:

• Rheumatology
• Immunology
• Neurology

Background:

• Idiopathic inflammatory myopathies (IIM) are autoimmune disorders with diverse clinical presentations, including muscle weakness, skin issues, and organ involvement.
• Diagnosing IIM is complex, traditionally relying on clinical signs, enzyme levels, imaging, and muscle biopsy.
• Recent discoveries of myositis-specific autoantibodies (MSAs) represent a significant breakthrough in understanding and managing IIM.

Purpose of the Study:

• To review the autoantibodies associated with various idiopathic inflammatory myopathy subtypes.
• To discuss the clinical applications and impact of these myositis-specific autoantibodies.

Main Methods:

• Literature review of recent advancements in myositis-specific autoantibodies.
• Analysis of diagnostic criteria evolution in IIM.
• Correlation of autoantibody levels with disease activity and treatment response.

Main Results:

• Myositis-specific autoantibodies (MSAs) have simplified the diagnostic process for IIM.
• MSAs aid in precise classification, clinical phenotyping, and prognostic stratification of IIM subtypes.
• Certain MSA levels correlate with disease activity and muscle enzyme levels, potentially predicting treatment outcomes.

Conclusions:

• Myositis-specific autoantibodies have revolutionized the diagnosis and management of idiopathic inflammatory myopathies.
• The use of MSAs refines patient stratification and offers insights into disease trajectory and therapeutic efficacy.